Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

Cancer

Volumn 86, Issue 12, 1999, Pages 2632-2641

  Sacchi, Stefano ^a   Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Rios, Mary Beth ^a   Giles, Francis J ^a   Beran, Miloslav ^a   Koller, Charles A ^a   Keating, Michael J ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blastic phase; Chronic myelogenous leukemia; Chronic myeloid leukemia; Decitabine; Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FAZARABINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; HYDROXYUREA; IDARUBICIN; MITHRAMYCIN; MITOXANTRONE; SEBRIPLATIN; TALLIMUSTINE; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BLAST CRISIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 0033572876     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A     Document Type: Article

References (47)

1. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JPJ. Alterations in DNA methylation - a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
2. Issa JPJ, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11:S7.
3. Zion M, Ben-Yehuda D, Auraham A, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1994;91:10722-6.
4. Willemze R, Suciu S, Archimbaud E, et al. A randomized Phase II study on the effects of 5-aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group Phase II study (06893). Leukemia 1997;11(Suppl 1): 24-7.
5. Wijermans PW, Krulder JW, Huijens PC, Neve P. Continuous infusion of low-dose 5-aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5.
6. Schwartsmann G, Fernandes MS, Schann MD, et al. Decitabine (5-aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 1997;11(Suppl 1):28-31.
7. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997;11:1617-20.
8. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987;83:445-54.
9. Kantarjian HM, Talpaz M, Kontoyannis D, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992;10:398-405.
10. Iacoboni SJ, Plunkett W, Kantarjian HM, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986;4:1070-88.
11. Kantarjian HM, Walters RS, Keating MJ, et al. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 1988;62:672-6.
12. Feldman E, Gandhi V, Plunkett W, et al. Sequential administration of fludarabine, ara-C, and mitoxantrone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia [abstract]. Blood 1992;84(Suppl 1):822.
13. Kantarjian HM, Beran M, Ellis A, et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993;81:1146-51.
14. Kantarjian HM, Beran M, O'Brien S, et al. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia 1996;10:396-401.
15. Beran M, Jeha S, O'Brien S, et al. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a Phase I study. Clin Cancer Res 1997;3:2377-84.
16. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187.
20. Winton EF, Miller D, Vogler WR. Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Cancer Treat Rep 1981;65:389-92.
21. Schiffer CA, De Bellis R, Kasdorf H, et al. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacytidine and VP-16-213. Cancer Treat Rep 1982;66:267-71.
22. Cervantes F, Rozman C, Blade J, et al. Treatment of blast crisis of chronic myelogenous leukemia with vincristine, prednisone, and cytarabine. Cancer Treat Rep 1985;69:923-4.
23. Schiffer CA, Anderson K, Coleman M, et al. Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azcytidine administered by continuous infusion: a Cancer and Leukemia Group B study. Cancer Treat Rep 1985;69:1027-8.
24. Uzuka Y, Saito Y. Treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone. Cancer Treat Rep 1985;69:1297-8.
25. Herzig RH, Phillips GL, Lazarus HM, et al. High-dose cytarabine for the treatment of blastic phase chronic myelogenous leukemia. Cancer Treat Rep 1985;69:881-3.
26. Koller CA, Miller DM. Preliminary observation on the therapy of myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 1986;315:1433-8.
27. Walters RS, Kantarjian HM, Keating MJ, et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and Adriamycin infusions plus high-dose decadron. Cancer 1987;60:1708-12.
28. Ernst TJ, Rosenthal DS, Griffin JD, et al. Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol 1988;11:623-6.
29. Anger B, Carbonell F, Braunger I, et al. Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Blut 1988;57:131-7.
30. Kreis W, Rottach C, Budman DR, et al. Pharmacokynetic and Phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. Cancer Res 1988;48:5580-4.
31. Spriggs DR, Robbins G, Arthur K, et al. Prolonged high-dose ara-C infusions in acute leukemia. Leukemia 1988;2:304-6.
32. Anger B, Heimpel H. Daunomycin, cytosine-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML. Blut 1989;58:299-301.
33. Dutcher JP, Eudey L, Wiernik PH, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1992;6:770-5.
34. Liang R, Chan TK, Chiu E, et al. Non-aggressive therapy for chronic myeloid leukemia in blastic transformation. Cancer Chemother Pharmacol 1992;29:323-5.
35. Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002-9.
36. Baduer F, Delmer A, Blanc MC, et al. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high-or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma 1993;10:195-200.
37. Kouides PA, Rowe JM. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leukemia Res 1995;19:763-70.
38. Amadori S, Picardi A, Fazi P, et al. A Phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia 1996;10:766-8.
39. Dutcher JP, Lee S, Paietta E, et al. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998; 12:1037-40.
40. Bortin M, Horowitz M, Rowlings P, et al., for the Advisory Committee of the International Bone Marrow Transplant Registry. 1993 Progress report from International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993;12:97-104.
41. Giralt S, Kantarjian HM, Talpaz M. Treatment of chronic myelogenous leukemia. Semin Oncol 1995;22:396-404.
42. Kantarjian HM, Talpaz M, Andersson B, et al. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant 1994;14:57-61.
43. Pinto A, Zagonel V. 5-Aza-2'-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodispastic syndromes: past, present and future trends. Leukemia 1993;7:51-60.
44. Kornblau SM, Xu H, Zhang W, Hu S, Beran M, Smith T, et al. Levels of retionoblastoma protein expression in newly-diagnosed acute myelogenous leukemia. Blood 1994;84:256-61.
45. Herman JG, Latiff F, Weng F, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
46. Otterson GA, Khleif SN, Chen W, et al. CDKN2 gene silencing in lung cancer by DNA hyper-methylation and kinetics of p16 protein induction by 5-aza-2'-deoxycytidine. Oncogene 1995;11:1211-6.
47. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Avraham A, Palumbo GA, Frassoni F, et al. Molecular follow-up of disease progression on interferon therapy in chronic myelocytic leukemia. Blood 1997;90:4918-23.